IMAGING FLOW CYTOMETER: CANCER

这个子项目是利用由NIH/NCRR资助的共享仪器赠款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是用于拨款的，而不一定是用于调查人员的机构。描述(由申请人提供)：Amennis ImageStream 100是第一台商用的成像流式细胞仪。它结合了流式细胞术(能够询问悬浮中的大量细胞的能力，成熟的颜色补偿、分析和显示方法)和图像分析(每个细胞的数字图像，从数字图像计算形态特征，荧光到形态特征的定位，荧光探针的共定位)的优点。一个由UPCI调查人员组成的核心小组领导了一项倡议，将这项尖端技术引入UPCI Flow设施。通过他们的努力，我们暂时使用了第一个商业ImageStream，它是以非资本租赁的方式放在设施中的。在我们接触到这一仪器的短短几周内，我们已经确认了它的能力，并进行了这项提议中描述的几个由研究人员发起的实验。该设施为42名NIH资助的研究人员提供服务，负责NIH资助的研究(直接成本)超过6800万美元。如果这项提议得到资助，我们将处于非常有利的地位，在将这项新技术应用于癌症、免疫学和细胞生物学研究方面发挥主导作用。

This subproject is one of many research subprojects utilizing the resources provided by a Shared Instrumentation Grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the grant, which is not necessarily the institution for the investigator. DESCRIPTION (provided by applicant): The Amnis ImageStream 100 is the first commercially available imaging flow cytometer. It combines advantages of flow cytometry (ability to interrogate large numbers of cells in suspension, well-developed color compensation, analysis and display methods) with those of image analysis (digital imagery of each individual cell, calculation of morphological features from digital images, localization of fluorescence to morphologic features, co-localization of fluorescent probes). A core group of UPCI investigators has led an initiative to bring this cutting edge technology to the UPCI Flow Facility. Through their efforts, we have the temporary use of the first commercial ImageStream, which was placed in the Facility on a non-capital lease basis. In the few short weeks that we have had access to this instrumentation we have confirmed its capabilities and performed several investigator-initiated experiments described in this proposal. The Facility serves 42 NIH-funded investigators, responsible for over $68 million in NIH-funded research (direct costs). Should this proposal be funded, we are very well positioned to play a leading role in applying this new technology to cancer, immunology, and cell biology research.